Liu, Ruiwu published the artcileStructure-activity relationship studies of a series of peptidomimetic ligands for α4β1 integrin on Jurkat T-leukemia cells, Application In Synthesis of 158922-07-7, the main research area is peptide solid phase synthesis SAR integrin ligand anticancer.
α4β1 Integrin is a therapeutic target for inflammation, autoimmune diseases, and lymphoid cancers. A series of peptidomimetic ligands based on the Nle-D-I motif have been synthesized and their binding affinities (IC50) to activated α4β1 integrin on Jurkat T-leukemia cells were determined using a cell adhesion assay. One of the 51 ligands, peptide I, has an IC50 = 0.6 nM, more than two fold increase of binding affinity than the initial lead compound II. Extensive SAR studies provided important information for further ligand optimization, which has served as a foundation for studies that ultimately led to identification of a potent ligand with an IC50 = 2 pM.
Biopolymers published new progress about Antitumor agents. 158922-07-7 belongs to class piperidines, name is 1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidine-3-carboxylic acid, and the molecular formula is C21H21NO4, Application In Synthesis of 158922-07-7.
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem